Abstract: Therapeutic treatments for a disease such as a cancer are disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer wherein the cancer cells overexpress arginine methyltransferase CARM1. In some embodiments, the therapeutic treatments disclosed include methods comprising the step of administering a therapeutically effective dose of an enhancer of zeste homolog 2 (EZH2) inhibitor to a subject, including a human subject, wherein the cancer cells of the subject overexpress arginine methyltransferase CARM1 and a PARP inhibitor. In some embodiments, the EZH2 inhibitors are administered in conjunction with platinum-based antineoplastic drugs.

Abstract: Therapeutic treatments for a disease such as a cancer are disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer wherein the cancer cells overexpress arginine methyltransferase CARM1. In some embodiments, the therapeutic treatments disclosed include methods comprising the step of administering a therapeutically effective dose of an enhancer of zeste homolog 2 (EZH2) inhibitor to a subject, including a human subject, wherein the cancer cells of the subject overexpress arginine methyltransferase CARM1 and a PARP inhibitor. In some embodiments, the EZH2 inhibitors are administered in conjunction with platinum-based antineoplastic drugs.

Abstract: Methods of treating cancer, promoting antigen presentation, or increasing CD8+ T cell infiltration in tumors by inhibiting KDMA5 are provided.

Abstract: The present disclosure is directed to the use of IRE-1 and/or XBP-1 inhibitors to treat cancers having mutations in ARID 1 A over overexpressing CARM1.

Abstract: Compositions and methods for treating cancer in a subject in need thereof is provided. In certain embodiments, the method includes administering therapy-induced senescent (TIS) cells and an immune checkpoint inhibitor to the subject. Also provided are compositions comprising therapy-induced senescent (TIS) cells.

Abstract: The present disclosure is directed to the use of inhibitors of glutamate metabolism to treat cancers that have mutations in ARID1A. Thus, in accordance with the present disclosure, there is provided a method of treating a subject determined to have an ARIDIA-mutated cancer, pre-cancer or benign tumor comprising administering to said subject at least one inhibitor of glutamate metabolism.

Abstract: In some embodiments, therapeutic treatments for a disease such as a cancer arc disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer wherein the cancer cells overexpress arginine methyltransferase CARM1. In some embodiments, the therapeutic treatments disclosed include methods comprising the step of administering a therapeutically effective dose of an enhancer of zeste homolog 2 (EZH2) inhibitor to a subject, including a human subject, wherein the cancer cells of the subject overexpress arginine methyltransferase CARM1. In some embodiments, the EZH2 inhibitors are administered in conjunction with platinum-based antineoplastic drugs.

Abstract: In some embodiments, therapeutic treatments for a disease such as a cancer are disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer wherein the cancer cells overexpress arginine methyltransferase CARM1. In some embodiments, the therapeutic treatments disclosed include methods comprising the step of administering a therapeutically effective dose of an enhancer of zeste homolog 2 (EZH2) inhibitor to a subject, including a human subject, wherein the cancer cells of the subject overexpress arginine methyltransferase CARM1. In some embodiments, the EZH2 inhibitors are administered in conjunction with platinum-based antineoplastic drugs.

Abstract: Therapeutic treatments for a disease such as a cancer are disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer wherein the cancer cells overexpress arginine methyltransferase CARM1. In some embodiments, the therapeutic treatments disclosed include methods comprising the step of administering a therapeutically effective dose of an enhancer of zeste homolog 2 (EZH2) inhibitor to a subject, including a human subject, wherein the cancer cells of the subject overexpress arginine methyltransferase CARM1 and a PARP inhibitor. In some embodiments, the EZH2 inhibitors are CA administered in conjunction with platinum-based antineoplastic drugs.

Abstract: In some embodiments, therapeutic treatments for a disease such as a cancer are disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer, wherein the cancer is an ARID1A-mutated cancer. In some embodiments, the therapeutic treatments disclosed include methods of treating ARID1A-mutated cancer in a subject comprising the step of administering a therapeutically effective dose of a histone deacetylase 6 (HDAC6) inhibitor to the subject, including a human subject. In some embodiments, the HDAC6 inhibitors are administered in conjunction with a therapeutically effective dose of an enhancer of zeste homolog 2 (EZH2) inhibitor.

Abstract: In some embodiments, therapeutic treatments for a disease such as a cancer are disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer wherein the cancer cells overexpress arginine methyltransferase CARM1. In some embodiments, the therapeutic treatments disclosed include methods comprising the step of administering a therapeutically effective dose of an enhancer of zeste homolog 2 (EZH2) inhibitor to a subject, including a human subject, wherein the cancer cells of the subject overexpress arginine methyltransferase CARM1. In some embodiments, the EZH2 inhibitors are administered in conjunction with platinum-based antineoplastic drugs.

Abstract: Systems, methods, and computer readable media for diagnosing or characterizing epithelial cancer or its stages based on the level of expression of the Wnt5a gene or protein are provided. The level of nucleic acids encoding Wnt5a or the level of Wnt5a protein is measured in a tissue sample, and the level is compared with reference values. Methods for inducing senescence of an epithelial cancer cell are also provided.

Abstract: A double-tubed instrument for endoscopic ligation is provided with two separate tubes with bands and a piston next to the last band mounted on the internal tube. The internal tube with bands and piston is put inside of the external tube; a flexible cone-shaped tubular adapter secured both tubes as a tubular instrument at one end, which connects the instrument at the inserting end of the endoscope. The piston moves freely between the tubes and secures completely a sealed space under from the cone-shaped tubular adapter creating a hydraulic tank between the piston and the cone-shaped tubular adapter, which is connected with a conduit for conveying liquid in and stores the liquid serving as the driving force to move bands forward and dislodge the aimed elastic band one at a time to effect the ligation of multiple lesions during a single insertion of the endoscope.

Abstract: A high-throughput method for identifying a compound or biomolecule that modulates cell senescence involves simultaneously measuring in a cell population exposed to the test compound or biomolecule, the expression of a senescence marker and cell number, wherein each well contains a single test compound; and determining from said simultaneous measurements whether the test compound increases or decreases cell senescence. In various embodiments, the method is useful is identifying compounds that delay the aging process of normal healthy cells, or identifying a compound useful as a tumor suppressor or identifying a compound useful in the treatment of cancer.

Abstract: Systems, methods, and computer readable media for diagnosing or characterizing epithelial cancer or its stages based on the level of expression of the Wnt5a gene or protein are provided. The level of nucleic acids encoding Wnt5a or the level of Wnt5a protein is measured in a tissue sample, and the level is compared with reference values. Methods for inducing senescence of an epithelial cancer cell are also provided.

Abstract: A double-tubed instrument for endoscopic ligation is provided with two separate tubes with bands and a piston next to the last band mounted on the internal tube. The internal tube with bands and piston is put inside of the external tube; a flexible cone-shaped tubular adapter secured both tubes as a tubular instrument at one end, which connects the instrument at the inserting end of the endoscope. The piston moves freely between the tubes and secures completely a sealed space under from the cone-shaped tubular adapter creating a hydraulic tank between the piston and the cone-shaped tubular adapter, which is connected with a conduit for conveying liquid in and stores the liquid serving as the driving force to move bands forward and dislodge the aimed elastic band one at a time to effect the ligation of multiple lesions during a single insertion of the endoscope.